Key terms
About ABOS
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABOS news
Yesterday
11:38am ET
These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
Apr 16
8:06am ET
Acumen presents first clinical, biomarker data for ACU193
Apr 04
8:20am ET
Acumen teams with Lonza for advancement of sabirnetug to treat AD
Apr 03
5:10am ET
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
Mar 31
11:05am ET
Acumen price target lowered to $14 from $15 at UBS
Mar 27
4:37pm ET
Acumen files $200M mixed securities shelf
Mar 27
7:21am ET
Acumen price target lowered to $11 from $22 at BTIG
Mar 19
8:22am ET
Acumen Pharmaceuticals Revises ALTITUDE-AD Study Phase
Mar 08
8:52am ET
Acumen presents sabirnetug fluid biomarker, target engagement analyses
Feb 21
8:04am ET
Acumen to present fluid biomarker, target engagement analyses from Phase 1 study
Feb 01
7:21am ET
Acumen appoints Doherty as President, Chief Development Officer
No recent press releases are available for ABOS
ABOS Financials
Key terms
Ad Feedback
ABOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
